跳至主要内容
临床试验/NCT01955343
NCT01955343已完成不适用

Immune Response in Lung Cancer

Lithuanian University of Health Sciences1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2012年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
1
主要终点
progression-free survival

研究概览

简要总结

This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Eastern Cooperative Oncology Group (ECOG) score of 0-1
  • Patients with histologically documented non-small cell lung cancer
  • Control group - patients without non-small cell lung cancer
  • Written (signed) Informed Consent to participate in the study

排除标准

  • Any other malignancies within 5 years
  • Any unstable systemic disease (including active infections, significant cardiovascular disease)
  • Prior chemotherapy or radiotherapy
  • Autoimmune disease
  • Nursing or pregnant women

结局指标

主要结局

progression-free survival

时间窗: one year after enrolment to the study

次要结局

  • overall survival(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marius Zemaitis

Assoc. Professor

Lithuanian University of Health Sciences

研究点 (1)

Loading locations...

相似试验

Immune Response in Lung Cancer | 临床试验